RAPH OTC
Raphael Pharmaceutical Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +536.4%
3Y: +35.9%
$1.40
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$28.2M
52W Range0.04-1.4
Volume140
Avg Volume147
Beta1.90
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOShlomo Pilo
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2023-01-05
Websiteraphaelpharmaceutical.com
4 Lui Paster
Jaffa, TA 6803605
IL
Jaffa, TA 6803605
IL
972 5 2775 5072
About Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering and clinically developing novel therapeutic solutions. These treatments primarily leverage cannabinoids and are designed to enhance patients' quality of life. Currently, the company's leading investigational drug candidate is being advanced for the management of rheumatoid arthritis. Furthermore, Raphael Pharma plans to broaden its pipeline to include more cannabinoid-based medicines aimed at various cancer types and other autoimmune conditions. The company's corporate headquarters are situated in Tel Aviv-Jaffa, Israel.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Louria Hayon Igal | X-InTheMoney | 350,000 | $0.01 | 2025-11-20 |
| Louria Hayon Igal | X-InTheMoney | 350,000 | $0.01 | 2025-11-20 |
| Laor Zvi Laufer | 0 | — | 2025-08-01 | |
| Eliya Yehuda | A-Award | 200,000 | $1.00 | 2025-03-10 |
| Dhadha Ajay Kumar | A-Award | 350,000 | — | 2025-03-05 |